We provide flexible high quality services to biopharmaceutical partners, enabling them to harvest on their research activities and to enter and supply their markets with the most efficient use of resources.
Our state of the art GMP manufacturing facilities and our experienced and dedicated team of people ensures manufacturing capabilities which meet the highest quality standards, a service oriented way of working and a flexible mindset.
HALIX focus is GMP manufacturing of biologics. We offer both the manufacturing of drug substance through mammalian cell culture, and aseptic fill and finish including lyophilization services.
As part of our continuous improvement and ongoing development, we are always extending the scope of our service offering for therapeutic proteins and viral vaccines. We are your partner as end-to-end service provider, supporting you from early development all the way to commercial supply on a global scale.
HALIX was founded in 2012 as a 100% subsidiary of HAL Allergy Holding B. V., internationally known as HAL Allergy Group. The HAL Allergy Group belongs to the family owned Droege Group AG.
HALIX combines ‘single point of contact’ project management with sound processes and procedures.From pre-clinical through commercialization, we provide high quality and flexible CDMO services to biopharmaceutical partners, enabling them to harvest on their research activities and to enter and supply their markets with the most efficient use of resources.
We currently operate a state of the art BSL2 facility in which we perform cell culturing activities, and in which we can work with genetically modified organisms (GMO’s). To meet your needs as you progress through your pipeline, we are extending our facility and the scope of services for therapeutic proteins and viral vaccines. Within the next years we are extending the capabilities of HALIX as end-to-end service provider, supporting you from early development all the way to commercial supply on a global scale.
Droege Group was founded in 1988. It is an independent advisory and investment company based in Düsseldorf, Germany. Since 25 years, the group is a specialist for customized transformation programs. Its aim is value enhancement. Droege Group employs its own funds to carry out direct investments. It invests in corporate subsidiaries and medium-sized enterprises. The goal is to hold and develop investments in the long run. The group achieves this via buy & build strategies (“Corporate Entrepreneurship”). Droege Group engages with equity in companies. It offers the same approach as a service provider in customized value-add engagements. This is “Entrepreneurship as a Service”. USP of the business model is know-how + capital + management from one single source. The family-owned company has a domestic and international market position. It enjoys a high reputation and operates in over 30 countries worldwide.